


## Life Sciences & Healthcare



Taylor Wessing has been voted:

**"European Life Science IP Firm of the Year"** at the Managing Intellectual Property Global Awards 2008; and

**"Law Firm of the Year"** - 2008 European Venture Capital Journal (EVCJ) Awards

Taylor Wessing is top-ranked in the latest editions of the following guides:

**PLC Cross-Border Life Sciences Handbook**

*Commercial & Partnering and Intellectual Property*

**Legal 500**

*Pharmaceutical & Biotech and Venture Capital  
M&A (Mid Market: £50 - £250 million)*

**Chambers**

*Life Sciences, Venture Capital and Patent Litigation*

Selected deals of Taylor Wessing's  
Life Sciences & Healthcare Group

## Partnering

### Asterand plc

Advised on a licence agreement granting Allergan Inc rights to further develop and commercialise compounds to treat eye conditions.

### Biota Holdings Ltd

Advised on an extended licence and collaboration agreement with AstraZeneca relating to a series of antivirals aimed at the treatment of respiratory syncytial virus.

### Biocompatibles International plc

Advising on the licence to Eisai of Biocompatibles' proprietary drug-eluting bead products in Japan.

### Myriad Genetics, Inc.

Advising Myriad Genetics, Inc. on its \$100 million licence to H Lundbeck A/S of European commercialization rights to the phase III product Flurizan for the treatment of Alzheimer's disease.

### Oxford BioMedica plc

Advised Oxford BioMedica on a global licence agreement worth US\$690 million with sanofi-aventis to develop and commercialise the cancer vaccine, Trovax®.

### Innate Pharma SA

Advised on a major strategic partnership with Novo Nordisk to develop drugs targeting natural killer cells involving a €10m investment in new Innate Pharma equity, expanding its collaboration with Novo Nordisk.

### Eyecopharm AG

Advising on the in-licensing from Ark Therapeutics Group plc of a number of compounds for development in the treatment of ocular diseases, in return for an equity stake in Eyecopharm and a royalty on sales.

### Biocompatibles International plc

Advised on distribution agreements with RITA Medical Systems Inc. and SciClone Pharmaceuticals in respect of Biocompatibles' LC and DC Bead embolisation products.

### SkyePharma plc

Advised SkyePharma on a collaboration agreement with PA Consulting Group to jointly develop a range of non-CFC propelled metered dose asthma products.

### Oxford BioMedica plc

Advised Oxford BioMedica plc on a collaboration with Sanofi-Aventis to develop novel gene-based medicines for the treatment of ocular diseases.

### UCB Celltech

Advised on an expanded product licence for Xyrem® (sodium oxybate) with Jazz Pharmaceuticals Inc. whereby UCB obtained the right to commercialise Xyrem for the treatment of fibromyalgia syndrome.

### Debiopharm Group

Advised Debiopharm Group on an exclusive agreement with Cambridge Antibody Technology to develop and market SC-1 for gastric carcinomas.

### Treague Limited

Advising Treague Limited on its collaboration with Geneva-based Medicines for Malaria Venture (MMV) for the development of RS(+) mefloquine for the treatment of malaria.

### EMcision Limited

Advised EMcision Limited a medical device company on a licensing and distribution deal with RITA Medical Systems Inc. for a novel liver surgery device.

### Xention Limited

Advised Xention Limited on a drug discovery agreement with Ono Pharmaceutical Co Ltd relating to the identification, design and synthesis of small molecules against selected ion channels.

### Genfit SA

Advised on its collaboration with Sanofi-Aventis regarding innovative targets involved in metabolic and inflammatory mechanisms.

### Trophos SA

Advised Trophos on its collaboration with the Association Française contre les Myopathies (AFM) in respect of spinal muscular atrophy.

### Innate Pharma SA

Advised Innate Pharma on its licence of novel Toll like receptor agents from Cancer Research UK.

### Genfit SA

Advised on its collaboration with Solvay SA on the identification and development of new selective nuclear receptor modulators playing a key role in the metabolism of lipoproteins.

### Sphere Medical Limited

Advised Sphere Medical on its collaboration and licensing agreement with Cranfield University in respect of molecularly imprinted polymers for clinical diagnostic applications.

## Venture Capital and Venture Debt

### MPM Capital

Advised a syndicate led by MPM Capital on its US\$59.8 million investment into Oxagen Limited, a drug discovery and development company specialising in inflammation.

### Apax Partners France & Merlin Biosciences

Advised on a US\$35 million private equity financing in a US biotech company specialising in the development of innovative sight-saving therapeutics for chronic retinal diseases.

### Advent Ventures & Scottish Equity Partners

Advised on an investment of £8 million into Rhytec Limited, a spin out from Gyrus Group plc, developing technologies for the dermatological, plastic and cosmetic surgery markets.

### Inventages

Advised on a £5.5million syndicated investment into Immunobiology Limited, a biotechnology company specialising in the treatment of infectious diseases and cancer.

## Domain Therapeutics

Advised Faust Pharmaceuticals SA (now Domain Therapeutics), a company dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors, on its new €2.11 million fundraising.

## Spark Ventures

Advised Spark Ventures on investing £1.24 million in drug development company Haemostatix Limited.

## Fovea Pharmaceuticals SA

Advised Fovea Pharmaceuticals SA, a company specialising in the development therapies for ophthalmic diseases, on its second financing round for a total amount of €30m led by Forbion Capital Partners.

## Vivacta Limited

Advised Vivacta Limited on its £6 million investment from AGF Private Equity, HBM BioVentures, Spark Ventures and Viking.

## Sphere Medical Limited

Advised Sphere Medical on the £4 million investment into it by various institutions.

## Xention Limited

Advised Xention Limited on raising up to £8 million from a range of institutional investors.

## Population Genetics Technologies Limited

Advised Population Genetics Technologies on its £3.8 million series A financing by Auriga Partners, Noble Fund Managers and Compass Genetics Investors LLC.

## Neurotech France SA

Advised Neurotech France and its existing investors, on a flip transaction into the US, leading to the incorporation of Neurotech Pharmaceuticals Inc.

## ETV Capital S.A.

Advised ETV Capital S.A. in connection with a venture loan made available to Chroma Therapeutics Limited and Macrotarg Limited.

## ETV Capital S.A.

Advised ETV Capital S.A. in connection with a venture loan made available to Decon Sciences Limited and Scantrack Healthcare Systems (UK) Limited.

## ETV Capital S.A.

Advised ETV Capital S.A. in connection with a venture loan made available to Plethora Solutions Holdings plc and Plethora Solutions Limited.

## ETV Capital S.A.

Advised ETV Capital S.A. in connection with a venture loan made available to Digital Healthcare Limited.

## M&A and Capital Markets

## Novathera Limited

Advised NovaThera on its merger with MedCell, to create a new UK company specialising in musculoskeletal regeneration.

## Novartis Institutes for BioMedical Research Inc

Advised Novartis on the completion of an option to subscribe for shares in Vernalis plc in connection with a collaboration agreement between the parties.

## Novartis AG

Advised Novartis on corporate law aspects of its €9 million investment in MorphoSys AG in the first step of a strategic collaboration between the two companies.

## Bayer HealthCare AG

Advised Bayer HealthCare on the divestment of the production of animal health biological vaccines to Intervet, a subsidiary of Akzo Nobel.

## DNA Research Innovations Limited

Advised on the sale of DNA Research Innovations for up to US\$65 million to Invitrogen Corporation.

## Biocompatibles International plc

Advised on the IP and IT aspects of the disposal of its cardiovascular stem business to Abbott Laboratories and its eye care division to the Cooper Group.

## Synergy Healthcare plc

Advised Synergy on its £14million placing and acquisition of the sterile services division of Hays Group plc.

## Oddo Corporate Finance

Advised the underwriter Oddo Corporate Finance on the IPO on the French Stock Exchange of animal health company Vétquinol.

## WaveLight AG

Advised on the strategic reorganisation of various business units and spinouts of WaveLight and the successful placement of a capital increase.

## Arthro Kinetics plc

Advised on the €9 million subscription and placing for Arthro Kinetics plc, an orthopaedics company dedicated to regenerating joint mobility. Investors included amongst others, funds controlled by Heidelberg Innovation.

## AOI Medical Inc

Advised AOI Medical, Inc. on its US\$2.6 million fundraising through the issue of senior convertible loan notes.

## Genus Pharmaceuticals

Advised Genus Pharmaceuticals on the £37.7 million acquisition of Forum Biosciences Holdings Limited.

**Berlin**  
Ebertstraße 15, 10117 Berlin  
Tel +49 (0)30 88 56 36 0  
Fax +49 (0)30 88 56 36 100

**Cambridge**  
24 Hills Road, Cambridge,  
CB2 1JP  
Tel +44 (0)1223 446400  
Fax +44 (0)1223 446401

**Düsseldorf**  
Benrather Straße 15  
D-40213 Düsseldorf  
Tel +49 (0)211 83 87 0  
Fax +49 (0)211 83 87 100

**Hamburg**  
Hanseatic Trade Center  
Am Sandtorkai 41, 20457  
Hamburg  
Tel +49 (0)40 36 80 30  
Fax +49 (0)40 36 80 3280

**Munich**  
Isartorplatz 8  
D-80331 Munich  
Tel +49 (0)89 2 10 38 0  
Fax +49 (0)89 2 10 38 300

**Brussels**  
Trône House, 4 Rue du Trône  
B-1000 Brussels  
Tel +32 (0)2 289 6060  
Fax +32 (0)2 289 6070

**Dubai**  
P.O. Box 33675  
28th Floor Al Moosa Tower II  
Sheikh Zayed Road  
Dubai, United Arab Emirates  
Tel +971 (0)4 332 3324  
Fax +971 (0)4 332 3325

**Frankfurt a. M.**  
Senckenberganlage 20-22  
D-60325 Frankfurt a. M.  
Tel +49 (0)69 971 30 0  
Fax +49 (0)69 971 30 100

**London**  
5 New Street Square  
London, EC4A 3TW  
Tel +44 (0)20 7300 7000  
Fax +44 (0)20 7300 7100

**Paris**  
42 avenue Montaigne  
75008 Paris  
Tel +33 (0)1 72 74 03 33  
Fax +33 (0)1 72 74 03 34

#### Representative offices:

**Alicante**  
Paseo Explanada de España  
No. 1  
4-lzda E-03002 Alicante,  
Spain  
Tel +34 (0)96 51 42 805  
Fax +34 (0)96 52 00 248

**Beijing**  
P.O. Box 33675  
Tower 2  
No. 5, Guanghua Road,  
Chaoyang District, Beijing  
100020, China  
Tel +86 10 8587 5886  
Fax +86 10 8587 5885

**Shanghai**  
15th Floor United Plaza,  
Unit 1509  
No. 1468, Nanjing West  
Road  
200040 Shanghai, China  
Tel +86 21 6247 7247  
Fax +86 21 6247 7248

#### Alliance with BSJP:

**Warsaw**  
Al. Armii Ludowej 26  
PL-00-609 Warszawa  
Tel. +48 (0) 22 579 89 00  
Fax. +48 (0) 22 579 89 01

[www.taylorwessing.com](http://www.taylorwessing.com)

## Taylor Wessing's Life Sciences & Healthcare Practice

Taylor Wessing has a dedicated Life Sciences & Healthcare Group, which provides a top quality, multi-disciplinary service. The Group combines Taylor Wessing's intellectual property, corporate, competition, dispute resolution, employment and real estate practices. We advise life sciences and healthcare businesses, those who fund them and those who work for them.

## An Overview of Taylor Wessing

Based principally in the UK, France, Germany, Belgium and Dubai with representative offices in Alicante, Beijing and Shanghai - Taylor Wessing provides the full range of legal services to major corporations, financial and public institutions, growing enterprises and wealthy private clients.

Taylor Wessing has an enviable track record in serving knowledge-based and technology-orientated businesses. A market leader in intellectual property and venture capital, the firm also has a strong market presence in corporate finance, private equity, real estate finance, inward investment and technology, media and telecoms.

Further information is available from [www.taylorwessing.com](http://www.taylorwessing.com).

## Our services

- **Partnering** - licensing, collaborations and joint ventures
- **Venture capital** - spin outs, start ups and financing rounds
- **Regulatory** - clinical trials, pharmaceutical and medical device approvals, pharmacovigilance, pricing, compliance programs, regulatory data protection and privacy
- **Corporate** - M&A, IPOs, private equity, tax, commercial law, inward investment and fund formation
- **Intellectual property** - all aspects including patent litigation, copyright, trade marks and confidential information
- **Competition** - EU law and anti-trust
- **Finance & projects** - banking, structured finance and major projects
- **Dispute resolution** - litigation, arbitration and mediation
- **Reconstruction and corporate recovery** - restructuring, work-outs and formal insolvency
- **Real estate** - Investment, development, finance and planning & environment
- **Employment & pensions** - employee benefits, human resources, pensions and pensions litigation
- **Private client** - international asset protection, tax and succession planning



Certificate No. EMS 532521

Taylor Wessing LLP is an ISO14001 environmentally certified partnership.

This marketing communication is printed on sustainably produced paper.

© Taylor Wessing LLP 2009

This publication is intended for general guidance only and no responsibility is accepted by Taylor Wessing LLP for any errors or omissions. The information in this publication should not be relied upon to replace professional advice on specific matters. Taylor Wessing LLP is a limited liability partnership registered in England and Wales, registered number 0C322935, with its registered office at 5 New Street Square, London, EC4A 3TW.

Taylor Wessing LLP operates in combination with associated legal entities in other locations.